EGFR and non-small cell lung carcinoma: In this retrospective study, we investigated predictive clinical biomarkers associated with osimertinib efficacy based on the profiles of NSCLC patients with the EGFR-T790M mutation after acquiring initial resistance to EGFR-TKIs.